Table 1 Baseline characteristics, comorbidities and outcomes between groups not screened compared to screened for latent tuberculosis infection using Quantiferon Gold
From: Tuberculosis screening practices and outcomes in an australian dialysis unit
Not screened | Screened | Significance | ||
|---|---|---|---|---|
Total | 243 | 229 | ||
Gender | Male | 164 (67.5%) | 140 (61.1%) | 0.15 |
Female | 79 (32.5%) | 89 (38.9%) | ||
Smoker | Never | 117 (48.2%) | 105 (45.9%) | 0.23 |
Former | 97 (39.9%) | 84 (36.7%) | ||
Current | 29 (11.9%) | 40 (17.4%) | ||
Age | 69 ± 10 | 52 ± 12 | < 0.001 | |
Risk in country of origin | Low < 10 per 100,000 population per year | 130 (53.5%) | 103 (45.0%) | > 0.05 |
Intermediate 10-100 per 100,000 population per year | 76 (31.3%) | 56 (22.5%) | > 0.05 | |
High > 100 per 100,000 population per year | 37 (15.2%) | 70 (30.5%) | < 0.001 | |
Lung disease | 32 (13.2%) | 21 (9.2%) | 0.17 | |
Coronary disease | 96 (39.5%) | 57 (24.9% | 0.001 | |
PVD | 48 (19.8%) | 33 (14.4%) | 0.12 | |
CVD | 40 (16.5%) | 22 (9.6%) | 0.02 | |
Diabetes | 159 (65.4%) | 122 (53.2%) | 0.007 | |
Immunosuppression | 14 (5.8%) | 23 (10.0%) | 0.08 | |
Cancer | 28 (11.5%) | 18 (7.9%) | 0.14 | |
Active TB | During study | 2 (0.9%) | 0.34 | |
Pre study | 4 (1.7%) | 4 (1.8%) | ||
Died | 84 (34.6%) | 32 (14.0%) | < 0.001 |